中国临床药理学杂志2017，Vol.33Issue(21)：2187-2191,5.DOI:10.13699/j.cnki.1001-6821.2017.21.026
肠促胰素类药物安全性系统评价再评价
Safety of incretin-based drugs for diabetes: an overview of systematic reviews
摘要
Abstract
Objective To systematic review which studied the safety of dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide -1 (GLP-1) receptor agonists for treatment of diabetes were searched from Cochrane Library,PubMed,CNKI,VIP,CBM and Wangfang database,and additional systematic reviews were searched by manual retrieval up to October 2016.Methodological qualities of the reviews were assessed by the a measurement tool for the assessment of multiple systematic reviews (AMSTAR) tool.The Meta-analysis was conducted by RevMan 5.3 software.Results A total of 46 systematic reviews were included in this overviews of systematic review.All the included studies were regarded as medium to high quality with more than 5 points by AMSTAR evaluation.When compared with placebo,DPP-4 inhibitors did not increase the risk of hypoglycemia,gastrointestinal,nasopharyngitis,headache,infection and cardiovascular adverse events,and slightly decreased body weight.Compared with other hypoglycemic agents,DPP-4 inhibitors had low incidence of hypoglycemia and cardiovascular adverse events.When compared with placebo,GLP-1 receptor agonists had a higher incidence of hypoglycemia and gastrointestinal adverse events,but did not increase the risk of nasopharyngitis,headache,cardiovascular adverse events and did not increase body weight.While compared with other hypoglycemic agents,GLP-1 receptor agonists had low incidence of hypoglycemia,high incidence of gastrointestinal reactions,and reducing body weight.Both DPP-4 inhibitors and GLP-1 receptor agonists did not increase the risk of pancreatitis.Conclusion DPP-4 inhibitors are safety,and GLP-1 receptor agonists increase hypoglycemia and gastrointestinal adverse events.关键词
糖尿病/二肽基肽酶-4抑制剂/胰高糖素样肽-1受体激动剂/Meta分析/系统评价再评价Key words
diabetes/dipeptidyl peptidase-4 inhibitor/glucagon-like peptide-1 receptor agonist/Meta-analysis/overviews of review分类
医药卫生引用本文复制引用
张建萍,钟黛云,卢丽清,许玥祺,李健..肠促胰素类药物安全性系统评价再评价[J].中国临床药理学杂志,2017,33(21):2187-2191,5.基金项目
广州市科技计划基金资助项目(201509010012) （201509010012）
